Hebei Kerui seizes the commanding point of biomedical materials research and development

[China Pharmaceutical network enterprise news] biomedical materials are the interdisciplinary fields involving a wide range of disciplines in contemporary science and technology, and are the important foundation of the two pillars of modern medicine - biotechnology and biomedical engineering It is in this field that Kerry studies and tackles In Hebei Kerui biomedical Co., Ltd located in Shijiazhuang Economic and Technological Development Zone, there is a spacious and atmospheric courtyard with trees and winding paths Occasionally, one or two workers walk by the courtyard in a hurry A Chinese Biomedical project that is about to be completed and put into operation is just around the corner "Made in Shijiazhuang" Zhixue Mian has stepped up to a four storey milky white building, minimally invasive intervention research center, Collagen Research Center, acellular tissue engineering research center, quality control center The technology research center of the company is arranged in turn, with a sense of preciseness, tidiness and standardization The technicians in white coats are busy with their own research, tense and orderly "Our project was built in 2014, covering an area of 100 mu, with an investment of 590 million yuan." Liu Shengjun, President of Hebei Medical Device Industry Association and chairman of Kerui company, said that they are aiming at the research and development and production of biomedical materials The products are very rich, including degradable biomedical materials, acellular biomedical materials and minimally invasive intervention biomedical engineering series products Many of the products are very cost-effective and belong to typical Shijiazhuang products From project approval to construction, Shijiazhuang Economic and Technological Development Zone has given strong support The head of Kerui biomedical company said that from the beginning of contact with the economic development zone to the signing, landing and production of the project, the economic development zone has given various supports For example, the approval procedures and links are obviously simplified compared with the previous ones; when there are problems in the project construction, the economic development zone helps to actively coordinate and solve them, which makes Kerui biology confident to grow and strengthen here In fact, the project has a modern biomedical material R & D center of 4000 square meters, equipped with advanced equipment and instruments and clean workshops in line with the national GMP standards A modern biomedical project has taken shape in the development zone "This is a kind of fast hemostatic material, which uses a lot of high-tech technologies and fills the gap in China." Liu Shengjun picked up a white package on the shelf and said that among the imported collagen hemostatic sponge products, Italian and American products dominate the domestic market and are expensive Kerui company, a national enterprise, started in Shijiazhuang and developed in the industry With the spirit of not giving up and not fearing losing, it made great efforts to overcome the technical difficulties After numerous failures, finally through the improvement of type I collagen extraction process and the exploration of freeze-drying process, it obtained high activity and high purity type I collagen hemostatic products, the quality is no worse than that of foreign countries, and the price is no lower But only 1 / 3 of the imported products Biomedical materials are the interdisciplinary fields involving a wide range of disciplines in contemporary science and technology, and are the important foundation of two pillars of modern medicine - biotechnology and biomedical engineering It is in this field that Kerry studies and tackles Now, this hemostasis product has carried out clinical research in Beijing 301 Hospital, Hebei People's Hospital, Bethune International Peace Hospital and other hospitals Breaking the Western monopoly of the biological patch "we have raised the technical platform to a strategic height, and vigorously built it from various aspects such as capital, personnel, equipment, service support, etc., so as to add resource elements such as projects, talents, information, etc., forming a sustained strong innovation ability." Xu Lanju, executive deputy general manager of Kerui company, said that they have established a number of technical platforms for research and development of acellular tissue engineering materials and collagen products For example, a series of biomaterial patch products, such as hernia patch, bladder patch and dural patch, have been developed based on the acellular tissue technology platform "This kind of biological patch, in short, is a three-dimensional scaffold structure formed by using natural tissue materials through acellular treatment, which can secrete new extracellular matrix components, form its own tissue, complete the repair and reconstruction of the defect tissue, and the range and quantity of materials are not limited, with good biocompatibility and low immune rejection Xu Lanju said At present, due to the limited source of the same kind of materials, the industrialization of foreign biological patches is limited; moreover, the price is expensive, and the preservation conditions are harsh; and Kerui's products can be preserved at room temperature, and the price is moderate Every year, there are 5 million patients in need of skin repair due to skin defects caused by burns and scalds, diabetic foot, varicose veins, vasculitis, etc Especially in some iron and steel enterprises, there are frequent burn events Many people have large area skin defects, which need large area repair In response to the market demand, Kerui company has developed xenogeneic acellular tissue engineering scaffolds, innovatively using new acellular technology and cross-linking modification method, which can realize the tissue regeneration of human repair cells, promote wound healing, and is expected to be widely used in the repair of burn and scald wounds This technology has filled the gap in our province and reached the domestic level At present, Beijing Jishuitan Hospital, Bethune International Peace Hospital and other medical institutions are carrying out in-depth cooperation, and patients in Shijiazhuang and Hebei are expected to use this product with moderate price and technology soon "The reason why we can have such technologies and products is that we are good at transforming the national and even the world's think tanks into real productivity through a series of cooperation." Liu Shengjun said that they have established a good cooperation mechanism with the PLA General Hospital, Nankai University, Russian Academy of Sciences, Northeastern University of Japan, Tachyon Co., Ltd and other domestic and foreign scientific research institutions, and have an expert advisory team including a number of well-known domestic academicians For example, the company and the Biochemical Research Institute of Russian Academy of Sciences launched a joint research on acellular tissue engineering scaffolds, making full use of the advanced scientific and technological concepts and technologies of foreign countries, accelerating the product development progress of Kerui in this area, and providing strong technical support for quickly seizing market share at home and abroad For another example, we have jointly carried out collagen hemostasis and repair technology research with Tachyon Co., Ltd., a Japanese enterprise in tissue engineering materials industry, and established a win-win cooperation relationship At present, we have applied for 7 projects, obtained 3 authorizations, and introduced 3 projects "We spend tens of millions of yuan every year to hire expert consultants and introduce technical cooperation." The person in charge of the company said that it is to build a good platform and make full use of these technical experts at all costs Shijiazhuang has a good development environment Many products will optimize the biomedical industrial structure of Shijiazhuang city after being listed, and gradually replace imports, benefiting the majority of patients.